Gluconic Acid

Gluconic Acid

SCHEMBL4141332

O.O.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Mn+2]

nearest known ligand 0.87

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHESCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A

The experimentally established mechanism targets of Gluconic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.87
PDE4A P27815 1/20 0.64
L3MBTL1 Q9Y468 1/20 0.50
USP2 O75604 1/20 0.48
SLCO1B1 Q9Y6L6 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
OR51E2 Q9H255 1/20 0.39
KDM4E B2RXH2 2/20 0.37
CYP2C9 P11712 1/20 0.32
TSHR P16473 1/20 0.32
CA4 P22748 2/20 0.31
TOP1 P11387 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gluconic Acid SCHEMBL21082704 1.00 LMNA (0.87) LMNAPDE4AL3MBTL1USP2SLCO1B1
Gluconic Acid SCHEMBL10799939 0.98 LMNA (0.91) LMNAPDE4AL3MBTL1USP2SLCO1B1
Gluconic Acid SCHEMBL21082705 0.98 LMNA (0.91) LMNAPDE4AL3MBTL1USP2SLCO1B1
Gluconic Acid SCHEMBL208644 0.98 LMNA (0.91) LMNAPDE4AL3MBTL1USP2SLCO1B1
Gluconic Acid SCHEMBL25181488 0.95 LMNA (0.87) LMNAPDE4AL3MBTL1USP2SLCO1B1
Gluconic Acid SCHEMBL19973172 0.95 LMNA (0.87) LMNAPDE4AL3MBTL1USP2SLCO1B1
Gluconic Acid SCHEMBL16416518 0.95 LMNA (0.95) LMNAPDE4AL3MBTL1USP2SLCO1B1
Gluconic Acid SCHEMBL23566696 0.95 LMNA (0.87) LMNAPDE4AL3MBTL1USP2SLCO1B1
SCHEMBL1884574 0.95 LMNA (0.87) LMNAPDE4AL3MBTL1USP2SLCO1B1
Gluconic Acid SCHEMBL22983955 0.95 LMNA (0.87) LMNAPDE4AL3MBTL1USP2SLCO1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250213524-A1 COMPOSITIONS FOR USE AMAZENTIS SA (CH) 2025-07-03 US claimed
WO-2025133367-A1 UROLITHIN COMPOUNDS FOR ENHANCING OR IMPROVING FERTILITY AMAZENTISSA (CH) 2025-06-26 WO claimed
US-20210161941-A1 Formulation for the Treatment of Polymorphisms in Methyl Metabolizing Genes and Methods of Treatment Thereof BEN TRE GAY B (US) 2021-06-03 US claimed
WO-2019147892-A1 FORMULATION FOR THE TREATMENT OF POLYMORPHISMS IN METHYL METABOLIZING GENES AND METHODS OF TREATMENT THEREOF BEN TRE GAY B (US) 2019-08-01 WO claimed
US-20090018865-A1 Earnest custom calibration system delivering dietary supplements EARNEST CARMELLA LYNN 2009-01-15 US claimed
EP-4710932-A1 COMPOSITIONS COMPRISING MANGANESE FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE Administración General de la Comunidad Autónoma de Euskadi (ES) 2026-03-18 EP disclosed
US-20250213524-A1 COMPOSITIONS FOR USE AMAZENTIS SA (CH) 2025-07-03 US disclosed
WO-2025133367-A1 UROLITHIN COMPOUNDS FOR ENHANCING OR IMPROVING FERTILITY AMAZENTISSA (CH) 2025-06-26 WO disclosed
US-20250064096-A1 MEAT-LIKE FOOD PRODUCTS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-02-27 US disclosed
US-12150464-B2 Meat-like food products BEYOND MEAT, INC. (US) 2024-11-26 US disclosed
US-11849741-B2 Meat-like food products WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-12-26 US disclosed
CN-108471779-B Meat analog food product 别样肉客公司 2022-07-26 CN disclosed
EP-2362725-B1 Antiviral supplement formulations VYMEDIC LLC (US) 2015-01-07 EP disclosed
US-20090104320-A1 Stabilization of Milk-Based Products WILD FLAVORS INC. (US) 2009-04-23 US disclosed
US-20060286207-A1 STABILIZATION OF MALT-BASED AND HOPS-BASED PRODUCTS WILD FLAVORS, INC. 2006-12-21 US disclosed
US-20050129825-A1 Stabilization of milk-based products GRAY KIMBERLEY H (US) 2005-06-16 US disclosed
EP-1425043-A1 METHOD OF INCREASING THE PRESENCE OF GLUTATHIONE IN CELLS N.V. Nutricia (NL) 2004-06-09 EP disclosed
WO-2003024487-A1 METHOD OF INCREASING THE PRESENCE OF GLUTATHIONE IN CELLS N.V. NUTRICIA (NL) 2003-03-27 WO disclosed
US-6495170-B1 PROPHYLAXIS OF LIVER DISORDERS BY ADMINISTERING PRODRUGS AND PROMOTERS OF GLUTATHIONE BIOSYNTHESIS, REGENERATION AND CONJUGATION N. V. NUTRICIA (NL) 2002-12-17 US disclosed
EP-0308983-A2 NMR imaging with Mn(II) coordination compositions SALUTAR, INC. (US) 1989-03-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250213524-A1 COMPOSITIONS FOR USE CYP17A1, ZYX, SHBG LMNA 2467/4885PDE4A 1357/4885L3MBTL1 4142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.